EFDID: 437290EFD: View Filing

Issuer: Aspargo Laboratories, Inc. (0001805092) - D

Accession: 0001753926-22-000348 (XMLRaw Data) (EDGAREDGAR Files) (Form DForm D)

EDGAR: Issuer Information
  • CIK:
    0001805092
  • Entity Name:
    Aspargo Laboratories, Inc.
  • Entity Type:
    Corporation
  • Jurisdiction:
    DELAWARE
  • Year of Inc:
    Within 5 years (2019)
  • Address:
    550 SYLVAN AVENUE, SUITE 102
    ENGLEWOOD CLIFFS, NJ 07632
  • Persons:
    Related Persons 3
    Michael Demurjian
    Executive Officer, Director, Promoter
    Michael Rice
    Director
    Fred Biehl
    Director
EDGAR: Offering Information
  • Accession Date:
    03/28/2022
  • First Sale Date:
    03/25/2022
  • Offering Amount:
    $60,000,000
  • Amount Sold:
    $1,531,998
  • Amount Remaining:
    $58,468,002
  • Exemptions:
    Rule 506
  • Security Type(s):
    Equity
EFD: Current State Notices
View Notices

Notices found in EFD

Filed:MA, MD, NJ, PA, TX
Inactive:NY, SC, WA
EDGAR: Sales Compensation Recipient Information
RecipientCRDBroker DealerBD CRDStates
Newbridge Securities Corporation 130814 None None FL, MD, MA, NJ, NY, PA, SC, TX, WA
EDGAR: Signatures
IssuerSignatureSigner NameTitleSignatureDate
Aspargo Laboratories, Inc./s/ Michael DemurjianMichael DemurjianCEO2022-03-28